BridgeBio Pharma (BBIO) said the first patient with non-small cell lung cancer ((NSCLC)) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's (BMY) Opdivo (nivolumab).
Xortx Therapeutics (XRTXF) (XRTX) reported data from a bridging pharmacokinetics trial of its proprietary formulation of oral oxypurinol, Xorlo being explored for kidney disease.The.
Relief Therapeutics (RLFTF)(RLFTD) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil).The company said the data showed high.
Akero Therapeutics (AKRO) said its drug efruxifermin ((EFX)) improved liver fibrosis without the worsening of liver disease, meeting the main goal of a Phase 2b study.The.